PatientsVille.com Logo

FIBROMYALGIA and Cyclobenzaprine

PatientsVille

FIBROMYALGIA Symptoms and Causes

Fibromyalgia is a disorder that causes muscle pain and fatigue. People with Fibromyalgia have "tender points" on the body. Tender points are specific places on the neck, shoulders, back, hips, arms, and legs. These points hurt when pressure is put on them.

People with Fibromyalgia may also have other symptoms, such as

  • Trouble sleeping
  • Morning stiffness
  • Headaches
  • Painful menstrual periods
  • Tingling or numbness in hands and feet
  • Problems with thinking and memory (sometimes called "fibro fog")

No one knows what causes Fibromyalgia. Anyone can get it, but it is most common in middle-aged women. People with rheumatoid arthritis and other autoimmune diseases are particularly likely to develop Fibromyalgia. There is no cure for Fibromyalgia, but medicine can help you manage your symptoms. Getting enough sleep, exercising, and eating well may also help.

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Check out the latest treatments for FIBROMYALGIA

FIBROMYALGIA treatment research studies

Cyclobenzaprine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Cyclobenzaprine Side Effects

Completed Suicide (160)
Toxicity To Various Agents (127)
Cardiac Arrest (64)
Respiratory Arrest (59)
Overdose (36)
Pain (28)
Cardio-respiratory Arrest (24)
Dizziness (24)
Confusional State (23)
Death (21)
Exposure Via Ingestion (20)
Nausea (18)
Fall (16)
Depression (15)
Convulsion (15)
Constipation (15)
Anxiety (14)
Hallucination (14)
Hypotension (14)
Headache (14)
Vomiting (13)
Fatigue (13)
Dry Mouth (12)
Chest Pain (12)
Deep Vein Thrombosis (12)
Dyspnoea (12)
Loss Of Consciousness (12)
Pulmonary Embolism (12)
Asthenia (11)
Heart Rate Increased (11)
Insomnia (11)
Somnolence (11)
Myoclonus (11)
Delirium (10)
Aspartate Aminotransferase Increased (10)
Coma (10)
Diarrhoea (10)
Intentional Overdose (10)
Hypoaesthesia (10)
Back Pain (9)
Alanine Aminotransferase Increased (9)
Depressed Level Of Consciousness (9)
Gait Disturbance (9)
Tachycardia (9)
Serotonin Syndrome (9)
Hepatic Function Abnormal (8)
Injury (8)
Tremor (8)
Psychotic Disorder (8)
Mental Status Changes (8)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Confusion, ringing of ears, dry (stinging) eyes, nightmares, depression associated with hyper-sensitivity/over-reaction in social events.

Im 16 yrs old and i have a bad lower back and neck so i take cylobenzapr and one time i fell asleep and awoke and was talking but not making no sense

<span style='font-family: Arial;'>I was subscribed Lyrica for my fibromyalgia and took it for about 3 weeks and as a result I ended up jumping through a window (resulting in permanent injuries) and wound up in a mental inst

<span style='color: #808080;'>I would like to share my experience with anyone that can read this.I have Fibromyalgia.I use guaifenesin to expell all the calcium phosphates from my body.I have been taking it over 6 years.Mucinex pretty much has

Afer five years of Famera treatment for breast cancer, I was anticipating feeling so much better. Now diagnosed with CFS and Fibromyalgia my doctor is trying to treat me lately with Chronic Behavorial Therapy. Yesterday my daughter took me to another

After long treatment with Nexium I got fibromyalgia. Do you thinsk Laprazol can be a solution or is it going to promote a similar side effect?

Does Amtriptyline help tinnitus. I'm taking it at a low dose for jaw problems and fibromyalgia. the 25 mg dose seems to make my tinnitus worse but my pain better. I don't know what to do?

Extreme muscle pain in legs, shoulders, neck and back. already had fibromyalgia and this was worse than any pain had previous to taking simvastatin. I was on it a yr. I had chonic insomnia, chest pain like pneumonia, so tired couldn't hardly move. co

Hello, My wife has severe fibromyalgia. I would like to try the Guaifenesin treatment for her. We can't seem to get our many doctors to do anything for her. Can you tell me what

Hey everyone with Fibro on this site talking about Mucinex, hear me: Mucinex is a med that is used to reverse your Fibro. It will make you sick. But it is supposed to. Please read: What Your Doctor May Not Tell You About Fibromyalgia" By Dr. St

Hey if you have Fibromyalgia and got sick on Mucinex, it's because you are supposed to. Please read the book:'What Your Doctor May Not Tell You About Fibromyalgia' by Dr. St. Amand. It's called the Guaifenisen Protocol and we use Mucinex/Guaifenisen

Hi Barbie, My sister has fibromyalgia and uses Magnesium plus malic acid for the pain. She also takes guaifenisen capsules and her fibro is managed much better. Maybe this will help.

FIBROMYALGIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Trial of Acupuncture in the Treatment of Fibromyalgia
Conditions: Fibromyalgia;   Diffuse Myofascial Pain Syndrome;   Fibromyalgia-Fibromyositis Syndrome;   Fibromyositis-Fibromyalgia Syndrome;   Myofascial Pain Syndrome, Diffuse
Interventions: Procedure: Acupuncture;   Behavioral: Orientation
Outcome Measures: Fibromyalgia Impact Questionnaire (FIQ) score;   Weekly Likert scale in pain diary;   Visual Analog Scale (VAS) for pain;   Short Form 36 (SF-36) score for quality of life;   Health Assessment Questionnaire - Disability Index (HAQ-DI) score;   Hospital Anxiety and Depression (HAD) Scale
2 Unknown  Prevalence of Fibromyalgia in Israel
Condition: Fibromyalgia
Intervention:
Outcome Measures: Prevalence of Fibromyalgia in the Israeli population;   Demographic data on Fibromyalgia patients
3 Not yet recruiting Fibromyalgia Integrative Training for Teens
Condition: Juvenile Fibromyalgia
Interventions: Behavioral: Fibromyalgia integrative training;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Average Pain Intensity;   Functional Disability;   Depressive Symptoms
4 Unknown  Occipital Transcranial Direct Current Stimulation in Fibromyalgia
Condition: Fibromyalgia
Intervention: Device: Transcranial direct current stimulation
Outcome Measures: Decrease on Visual Analogue Scale (VAS) score for Fibromyalgia related pain and pain scales of the Fibromyalgia Impact Questionnaire;   Changes in scores of the pain vigilance and awareness questionnaire, pain catastrophizing scale, Fibromyalgia impact questionnaire and modified Fatigue Impact Scale
5 Recruiting Neurodynamic Intervention in Fibromyalgia
Condition: Fibromyalgia
Interventions: Other: Neurodynamic technique group;   Other: Placebo group
Outcome Measures: Nervous assessment;   Manual dexterity;   Grip strength;   Pressure pain measure
6 Recruiting Tai Chi and Aerobic Exercise for Fibromyalgia (FMEx)
Condition: Fibromyalgia
Interventions: Behavioral: Lower frequency, shorter period of Tai Chi;   Behavioral: Higher frequency, shorter period of Tai Chi;   Behavioral: Shorter frequency, longer period of Tai Chi;   Behavioral: Higher frequency, longer period of Tai Chi;   Behavioral: Aerobic Exercise Training
Outcome Measures: Change in Fibromyalgia Impact Questionnaire (FIQ) from baseline to 24 weeks;   Change in Fibromyalgia Impact Questionnaire at follow-up;   FM Symptom Severity Scale;   Body Mass Index (BMI);   Medical Outcome Study Short Form 36 (SF-36);   Patient Global Assessment;   The Beck Depression Inventory II;   The Chronic Pain Self-Efficacy Scale (CPSS);   The Pittsburg Sleep Quality Index (PSQI);   The Sleep Quality Numeric Rating Scale (NRS);   6-Minute Walk;   The Chair Stand Test;   The brief Outcome Expectation Scale (OES);   Health Assessment Questionnaire (HAQ);   PROMIS Health Assessment Questionnaire (HAQ);   Muscle Strength/Power and Balance;   CHAMPS Activities Questionnaire for Older Adults
7 Recruiting Dance-movement Therapy Programme in Fibromyalgia.
Condition: Fibromyalgia
Interventions: Other: Dance-movement therapy;   Other: Control group
Outcome Measures: Changes in balance;   Changes in quadriceps strength;   Changes in quality of life;   Changes in flexibility of lower limbs
8 Unknown  Influenza Vaccination in Fibromyalgia Patients
Condition: Fibromyalgia Syndrome
Interventions: Biological: Inactivated split virion Influenza vaccine;   Biological: WHO recommended 2011 Influenza vacccine
Outcome Measures: proportion of patients who achieve a titer of antibodies above 1/40, against each of the antigens included in the vaccine;   Number of adverse events;   Clinical changes post - vaccination
9 Recruiting Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia
Condition: Fibromyalgia
Intervention: Procedure: Transcranial Direct Current Stimulation (tDCS)
Outcome Measures: Glu levels within the insula and thalamus will be reduced following tDCS;   Cortical thickness in FM patients, will return to comparable age- and sex-matched pain-free control participant levels following tDCS
10 Unknown  Exercise in Women With Fibromyalgia
Condition: Fibromyalgia
Interventions: Behavioral: water-based exercise;   Behavioral: land-based exercise intervention;   Behavioral: Control group
Outcome Measures: Overall impact of Fibromyalgia;   Tenderness;   Visual analogic scale for pain;   The Pain Catastrophizing Scale;   Body composition;   Functional capacity;   Fatigue;   Sleep Quality;   Health-related quality of life;   Cognitive function
11 Recruiting Immune-Pineal Axis Function in Fibromyalgia
Condition: Fibromyalgia
Interventions: Drug: Melatonin and Placebo;   Drug: Amitriptyline and Placebo;   Drug: Melatonin and Amitriptylin
Outcome Measures: Change from Baseline in pain on Fibromyalgia Impact Questionnaire (FIQ) at week 6;   Change from Baseline in Pain Pressure Threshold (PPT) at week 6;   Change from Baseline Brain-derived neurotrophic factor at week 6;   Change from Baseline of the Pittsburgh Sleep Quality Index (PSQI) at week 6;   Change from Baseline of the Pain Catastrophizing Scale at week 6
12 Unknown  Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)
Conditions: Fibromyalgia;   Systemic Lupus Erythematosus
Intervention:
Outcome Measure: Fatty acid composition of RBC membrane
13 Not yet recruiting A Randomized Trial of Oral Iron Therapy in Fibromyalgia
Condition: Primary Fibromyalgia
Interventions: Drug: Oral Iron;   Drug: Oral Placebo
Outcome Measures: Widespread Pain Index;   Symptom Severity Scale score;   Hindi version of Fibromyalgia Impact Questionnaire;   Visual Analog Scale for pain;   Hindi version of Brief Physical Health Questionnaire;   Hindi version of SF-36 questionnaire.
14 Recruiting Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia
Condition: Fibromyalgia
Interventions: Dietary Supplement: PERMEAPROTECT;   Dietary Supplement: PLACEBO
Outcome Measures: Improvement of the Gastrointestinal Quality of Life Index (GIQLI) at the end of the supplementation period (5 weeks), compared with baseline.;   Improvement of the Gastrointestinal Quality of Life Index (GIQLI) at end of follow-up (2 weeks), compared with baseline;   Improvement of the Impact of Fibromyalgia on the Quality of life, measured by the Fibromyalgia Impact Questionnaire (FIQ), at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Improvement of the subjective evaluation, by the patient, of the intensity of gastrointestinal symptoms, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Improvement of the subjective evaluation, by the patient, of the satisfactory relief of gastrointestinal symptoms, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Improvement of the subjective evaluation, by the patient, of the satisfactory relief of gastrointestinal pain, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Reduction of the serum C-reactive Protein (usCRP), measured by the ultra-sensitive method, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Reduction of the intestinal permeability, measured by the urinary ratio of lactulose/mannitol, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Reduction of blood oxidative stress markers (reduced glutathione, oxidized glutathione and malondialdehyde), at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.;   Improvement of the general Quality of Life, measured by the Medical Outcome Study Short Form (MOS SF-36), at the end of the supplementation period (5 weeks), and at the en of follow-up (2 weeks), compared with baseline
15 Recruiting Cyclobenzaprine Extended Release (ER) for Fibromyalgia
Conditions: Fibromyalgia;   Pain;   Sleep;   Fatigue
Interventions: Drug: cyclobenzaprine ER (AMRIX);   Drug: placebo
Outcome Measures: Visual Analogue Pain Scale;   Brief Fatigue Inventory;   Analogue sleep/wakefulness scale;   Fibromyalgia Impact Questionnaire;   Sheehan Disability SCale;   Quick Inventory of Depression;   Reported Adverse Effects
16 Recruiting Efficacy of a Gluten-free Diet for the Treatment of Fibromyalgia
Condition: Fibromyalgia
Interventions: Other: Gluten-free diet;   Other: Hypocaloric diet
Outcome Measures: Change, between baseline and endpoint, in the number of experienced celiac-type symptoms;   Change, between baseline and endpoint, in the Body Mass Index;   Change, between baseline and endpoint, in the Revised Fibromyalgia Impact Questionnaire total score;   Change, between baseline and endpoint, in the Pittsburgh Sleep Quality Index;   Change, between baseline and endpoint, in the Brief Pain Inventory;   Change, between baseline and endpoint, in the Beck Depression Inventory;   Change, between baseline and endpoint, in the Short-form Health Survey;   Change, between baseline and endpoint, in the State-Trait Anxiety Inventory
17 Recruiting Adolescent Fibromyalgia Study
Condition: Fibromyalgia
Interventions: Drug: placebo;   Drug: pregabalin (Lyrica)
Outcome Measures: Endpoint mean pain score from daily pain diary;   Endpoint mean sleep quality score from the daily sleep diary;   Pain Numeric Rating Scale (Pain-NRS) at Termination Visit;   Patient Global Impression of Change at Termination;   Parent Global Impression of Change at Termination Visit;   Fibromyalgia Impact Questionnaire for Children at Termination Visit;   Frequency and severity of adverse events at every visit.;   Physical and neurological exams.;   Vital signs.;   Suicidality Tracking Scale (STS).;   12-Lead Electrocardiogram (ECG).;   Laboratory tests: hematology, chemistry, serum pregnancy, urinalysis.;   Reproductive hormone monitoring (females only);   Tanner staging-assessment of pubertal status (females only);   Pharmacokinetic endpoint: A population pharmacokinetic analysis will be performed using the sparse PK samples obtained at V6.
18 Unknown  Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia
Condition: Fibromyalgia
Interventions: Drug: Tetrahydrocannabinol;   Drug: Placebo
Outcome Measures: Meaningful change in Total score on Fibromyalgia Impact Questionnaire (FIQ);   Meaningful change in Brief Pain Inventory average pain severity.
19 Recruiting Pain Sensitivity of Subjects With Fibromyalgia Before and After Repetitive Transcranial Magnetic Stimulation Treatment
Condition: Fibromyalgia
Intervention: Other: experimental pain induction
Outcome Measures: Variation in the Visual Analogic Scale (VAS)score after fixe pressure application (160 kPa) between the first rTMS session (T0) and the last rTMS session (T21)in relation to clinical improvement;   variation in the experimental pain feeling (VAS) between T0 and T21 in relation to treatment group;   variation in experimental pain feeling between T0 and T210 (the end of rTMS maintenance sessions);   variation in Beck Depression Inventory scores between T0 and T21;   variation in Fibromyalgia Impact Questionnaire score between T0 and T21
20 Recruiting A Study For Pregabalin In Patients With Fibromyalgia
Condition: Fibromyalgia
Interventions: Drug: pregabalin;   Drug: placebo
Outcome Measures: Relief of pain associated with Fibromyalgia by comparing with the baseline, the difference for endpoint mean pain score ( the mean of the last 7 pain diary entries) in the double-blind treatment period between pregabalin and placebo groups;   Safety and tolerability measures include evaluating the nature, frequency and intensity of adverse events and subject discontinuations. The Suicidality assessment (STS) is also included.;   Secondary efficacy endpoints include sleep, fatigue, health-related quality of life, functioning, pain, and mood disturbance will be assessed using MOS-S, Daily Sleep Diary and Subjective Sleep Questionnaire(SSQ), MAF, SF-36, VAS, HADS.